首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | THPO |
| Uniprot No | P40225 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-353aa |
| 氨基酸序列 | SPAPPACDLRVLSKLLRDSHVLHSRLSQCPEVHPLPTPVLLPAVDFSLGEWKTQMEETKAQDILGAVTLLLEGVMAARGQLGPTCLSSLLGQLSGQVRLLLGALQSLLGTQLPPQGRTTAHKDPNAIFLSFQHLLRGKVRFLMLVGGSTLCVRRAPPTTAVPSRTSLVLTLNELPNRTSGLLETNFTASARTTGSGLLKWQQGFRAKIPGLLNQTSRSLDQIPGYLNRIHELLNGTRGLFPGPSRRTLGAPDISSGTSDTGSLPPNLQPGYSPSPTHPPTGQYTLFPLPPTLPTPVVQLHPLLPDPSAPTPTPTSPLLNTSYTHSQNLSQEG |
| 预测分子量 | 36.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于THPO重组蛋白的3-4篇参考文献及其摘要概括：
1. **文献名称**: *Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin*
**作者**: Kaushansky, K. et al.
**摘要**: 该研究首次报道了人源THPO基因的克隆，证实其通过结合c-Mpl受体刺激巨核细胞增殖与分化，并显著提升动物模型中的血小板水平，为THPO的生物学功能奠定基础(Nature, 1994)。
2. **文献名称**: *Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl*
**作者**: Bartley, T.D. et al.
**摘要**: 研究团队独立分离出THPO蛋白(命名为MGDF)，阐明其通过激活Mpl受体信号通路促进巨核细胞成熟，为重组THPO的临床应用提供理论支持(Cell, 1994)。
3. **文献名称**: *Effects of recombinant human thrombopoietin in patients with chemotherapy-induced thrombocytopenia*
**作者**: Vadhan-Raj, S. et al.
**摘要**: 临床试验显示，重组人TPO(rhTPO)可显著缩短化疗患者血小板减少的持续时间并降低输血需求，验证了其治疗潜力(Blood, 1997)。
4. **文献名称**: *New thrombopoietic growth factors*
**作者**: Kuter, D.J.
**摘要**: 综述总结了TPO类似物(如romiplostim和eltrombopag)的研发进展，讨论其通过不同机制激活Mpl受体，在免疫性血小板减少症(ITP)等疾病中的疗效(Blood Reviews, 2007)。
这些文献涵盖了THPO的基础研究、临床转化及药物开发，反映了其在血液学领域的重要性。
Thrombopoietin (THPO), a glycoprotein hormone primarily produced in the liver and kidneys, plays a critical role in regulating platelet production by binding to the c-MPL receptor on megakaryocytes. Discovered in the 1990s, THPO stimulates megakaryocyte proliferation, differentiation, and platelet release, making it a key therapeutic target for thrombocytopenia. However, native THPO has limitations, including instability and immunogenicity, prompting the development of recombinant THPO analogs.
Recombinant THPO proteins are engineered using genetic modification techniques, such as expression in mammalian cell systems (e.g., CHO cells) or Escherichia coli. These proteins mimic the biological activity of endogenous THPO but are optimized for enhanced stability, prolonged half-life, and reduced immune reactions. Examples include romiplostim, a peptibody with THPO-mimetic domains, and eltrombopag, a small molecule agonist of the c-MPL receptor. Such agents bypass the challenges of natural THPO, offering controlled pharmacokinetics and scalable production.
Clinically, recombinant THPO proteins are used to treat chronic immune thrombocytopenia (ITP), chemotherapy-induced thrombocytopenia, and hepatitis C-associated thrombocytopenia. They reduce bleeding risks and dependency on platelet transfusions. Research also explores their potential in bone marrow failure syndromes and post-transplant platelet recovery. Despite their efficacy, long-term safety concerns, such as thrombosis risk and bone marrow fibrosis, require ongoing monitoring.
Overall, recombinant THPO represents a milestone in hematology, bridging molecular biology insights with therapeutic innovation to address platelet disorders. Ongoing studies aim to refine dosing, minimize side effects, and expand applications, underscoring its significance in precision medicine.
×
